Entera Bio Ltd (ENTX) News
Filter ENTX News Items
ENTX News Results
|Loading, please wait...|
ENTX News Highlights
- ENTX's 30 day story count now stands at 2.
- Over the past 1 day, the trend for ENTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO, DRUG and PATH are the most mentioned tickers in articles about ENTX.
Latest ENTX News From Around the Web
Below are the latest news stories about Entera Bio Ltd that investors may wish to consider to help them evaluate ENTX as an investment opportunity.
Maxim Group analyst Jason McCarthy reiterated a Buy rating on Entera Bio (ENTX – Research Report) yesterday and set a price target of $10.00. The company's shares closed last Wednesday at $2.93. According to TipRanks.com, McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.7% and a 22.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. Currently, the analyst consensus on Entera Bio is a Moderate Buy with an average price target of $10.50.
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), today announced it has concluded its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on EB613, its oral formulation of human parathyroid hormone (1-34), or PTH, for the treatment of osteoporosis and defined the path for Phase 3 development of EB613, confirming that a fracture study will not be necessary and that
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Analyst Ratings This is a summary of recent ratings and price targets for Kodiak Sciences and 
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Volatility & Risk Kodiak Sciences has a beta of 1.39, indicating that its stock price is 
Entera Bio Ltd. (NASDAQ:ENTX) Stock analysts at B. Riley lifted their FY2021 earnings estimates for shares of Entera Bio in a research note issued to investors on Thursday, November 11th. B. Riley analyst K. Patel now anticipates that the company will post earnings of ($0.77) per share for the year, up from their previous 
Entera Bio (NASDAQ:ENTX) released its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts consensus estimates of ($0.12) by $0.03, Fidelity Earnings reports. Entera Bio had a negative return on equity of 161.80% and a negative net margin of 3,414.71%. Entera Bio stock traded up $0.02 
Two Presentations at ASB M R , including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis
No summary available.
Knoll Capital Management LLC increased its position in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 38.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,484,275 shares of the company’s stock after acquiring an additional 692,912 shares during the period. […]
Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the Holy Grail of drug development.